格隆汇8月19日丨大成生化科技(00809.HK)宣布，董事会会议将于2025年8月29日举行，藉以（其中包 括）审议及批准本公司及其附属公司截至2025年6月30日止六个月的未经审核中期业绩及考虑派发中期 股息（如有）。 ...

* 承董事會命 大成生化科技集團有限公司 公司秘書 陳昇輝 00809 董事會會議通告 大成生化科技集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，董事會會 議將於二零二五年八月二十九日舉行，藉以（其中包括）審議及批准本公司及其附屬公司 截至二零二五年六月三十日止六個月之未經審核中期業績及考慮派發中期股息（如有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 香港，二零二五年八月十九日 於本公告日期，董事會成員包括兩名執行董事王成先生及王貴成先生；一名非執行董事 李躍文先生；及三名獨立非執行董事姜芳芳女士、譚超先生及解梁秋女士。 * 僅供識別 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 大成生化科技集團有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00809 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | | 0.1 HKD | | 3,000,000,000 ...

Group 1 - The core point of the article highlights a significant drop in the stock price of Da Cheng Biochemical Technology, which fell by 10.0% to 0.099 yuan per share, with a trading volume of 3.9634 million yuan as of 15:30 on August 4 [1] - Da Cheng Biochemical Technology Group Limited is identified as a leading manufacturer of corn biochemical products in China, focusing on the production and sale of corn refining products [1] - The company is headquartered in Hong Kong, with its main production base located in the corn golden belt of Jilin Province [1] Group 2 - As of the 2024 annual report, Da Cheng Biochemical Technology reported total operating revenue of 1.853 billion yuan and a net profit of 713 million yuan [2]

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]

锅炉翻修项目，其中包括：(i)新建一套150吨╱小时超高温超高压循环流化床锅炉，配套新供热装置设 施;(ii)建造烟气除尘和脱硝装置，重新使用现有的脱硫装置;(iii)建立新的除渣和输灰、装煤和除尘系统; (iv)建立新的全膜海水淡化水系统(部分重复使用现有组件);(v)安装热供仪表和控制系统，同时进行集成 控制改造;(vi)建设相关的综合自动化系统和更新塬有系统(包括厂房区域的排水和供水系统、供暖、通 风和空调(HVAC)系统以及相关的绿化及铺装)。 智通财经APP讯，大成生化科技(00809)发布公告，招标已于2025年7月14日成功收标，而长春大合(公司 全资附属公司)已于2025年7月31日与联合中标者东北电力及辽宁电力订立EPC合约。根据EPC合约，承 包商将负责锅炉翻修项目的项目工程设计、采购、施工、安装、校准及测试运行相关工作，最高代价为 人民币1.291亿元(包括提前竣工最高奖金)。 ...

Core Viewpoint - The company has successfully awarded an EPC contract for a boiler renovation project, which is essential for enhancing operational efficiency and competitiveness in the market [1][2] Group 1: Project Details - The EPC contract was signed on July 31, 2025, with a maximum cost of RMB 129.1 million, including potential early completion bonuses [1] - The boiler renovation project includes the construction of a new 150 tons/hour ultra-high temperature and ultra-high pressure circulating fluidized bed boiler, along with various supporting systems [1] - Additional components of the project involve the establishment of flue gas dust removal and denitrification systems, a new seawater desalination system, and upgrades to existing automation and control systems [1] Group 2: Strategic Importance - The renovation is necessary due to the outdated boiler facilities that have been in use for over 20 years, which limits the company's cost-effectiveness and sustainability [2] - The company primarily engages in the production and sale of corn refining products and biochemical products, and lacks the qualifications and capabilities for similar large-scale renovation projects [2] - By outsourcing the boiler renovation project to a qualified EPC contractor, the company aims to reduce administrative costs and select high-quality suppliers through competitive bidding [2]

00809 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED * 有關以公開招標方式訂立的EPC合約的須予披露交易 以公開招標方式訂立EPC合約 茲提述本公司日期為二零二五年五月二十三日有關就EPC合約開始公開招標的公告。 以公開招標方式訂立EPC合約 茲提述本公司日期為二零二五年五月二十三日有關就EPC合約開始公開招標的公告。 誠如本公司日期為二零二五年五月二十三日的公告所披露，長春大合已就EPC合約發出招 標公告邀請投標者，該招標已於二零二五年五月二十六日開始。由於並無足夠的投標者 參與該招標，長春大合已分別於二零二五年六月三日（已於二零二五年六月二十三日截 止，無中標者）及二零二五年六月二十四日發出另外兩份招標公告，邀請投標者競投EPC 合約。於日期為二零二五年六月二十四日的招標公告中，為激勵承包商參加招標，已加 入提供的獎金的條款以獎勵提前竣工鍋爐 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 00809 涉及根據特別授權發行代價股份之 供應商債務重組安排 延遲寄發通函 茲提述大成生化科技集團有限公司（「本公司」）日期為二零二五年七月八日之公告（「該公 告」），內容有關涉及根據特別授權發行代價股份之供應商債務重組安排。除文義另有所 指外，本公告所用詞彙與該公告所界定者具有相同涵義。 由於需要額外時間編製及落實將納入通函（「通函」）的若干資料，誠如該公告所述，其應 載有（其中包括）(i)股份購買協議及其項下擬進行交易（包括重新收購及授出發行代價股份 之特別授權）之進一步資料；(ii)股東特別大會通告；及(iii)上市規則規定須予披露之其他 資料，預期通函寄發予股東的日期將延遲至二零二五年八月二十二日或之前。 承董事會命 大成生化科技集團有限公司 主席 王成 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED * 香港，二零二五年七月三十一日 於本公告 ...

格隆汇6月9日丨大成生化科技(00809.HK)公告，为促成供应商债务重组安排，相关供应商近期已专为供 应商债务重组安排设立供应商中国合伙企业。所有供应商中国合伙企业均以相同方式设立，因此所有相 关供应商参照集团结欠彼等的应付款项金额享有供应商债务重组安排项下的同等权利。 于2025年6月9日，(i)各供应商中国合伙企业(作为初始债权人及认购人)；(ii)世纪大成(作为债务人及发 行人)；(iii)公司全资附属公司及世纪大成直接股东大成生化科技集团有限公司("大成香港")订立各份债 转股协议。根据债转股协议，各供应商中国合伙企业将动用各供应商债务金额(合共人民币461.1百万元) 认购世纪大成新增注册资本，于完成后，该等资本应视为已缴足注册资本，合共占世纪大成约28.98% 股权。 债转股协议完成须待集团取得所有监管同意及授权，包括但不限于商务部主管部门所要求的批准或备案 后，方告作实。债转股协议完成后，世纪大成将由供应商中国合伙企业合共持有约28.98%，及由大成 香港持有约71.02%。世纪大成将仍为公司附属公司。债转股协议已包含禁售条款，据此供应商中国合 伙企业所持世纪大成任何股权仅可为供应商债务重组安 ...